Stephen Dilly

President and Chief Executive Officer at CODEXIS

Board

Since August 2022

Age

65 years

Education

Holds an M.B.B.S. and a Ph.D. in cardiac physiology from the University of London.

Tenure

Joined as a director in June 2020, became President and CEO in August 2022, and was promoted to Chairman in August 2024.

Also at CODEXIS

Alison Moore

Chief Technical Officer

Georgia Erbez

Chief Financial Officer

Kevin Norrett

Chief Operating Officer

About

Stephen Dilly is a seasoned executive in the life sciences industry, recognized for his leadership and extensive experience in drug development. He holds an M.B.B.S. and a Ph.D. in cardiac physiology from the University of London, and he is 65 years old as of Q1 2025.

He joined Codexis as a director in June 2020 and advanced to President and Chief Executive Officer in August 2022. Later, his leadership was further recognized when he was promoted to Chairman in August 2024.

Throughout his career, he has held pivotal roles in various companies within the biotechnology and pharmaceutical sectors, demonstrating a strong record in operational leadership and strategic development.

His tenure at Codexis underscores a commitment to driving growth and innovation, reflecting a career built on years of executive experience and industry expertise.

$CDXS Performance Under Stephen Dilly

Past Roles

Organization	Role	Date Range	Details
Cognoa, Inc.	Board Member	2018 - 2024	Digital healthcare company board role
Codexis, Inc.	Director	June 2020 - August 2022	Served before his appointment as President & CEO
Sierra Oncology	Chief Executive Officer	May 2020 - July 2022	Role ended with acquisition by GlaxoSmithKline
Sangamo Therapeutics, Inc.	Board Member	2010 - September 2020	Public genomic therapies company role
Aimmune Therapeutics	CEO & Board Member	April 2014 - June 2018 (CEO), April 2013 - June 2018 (Board)	Acquired by Nestlé Health Science
PhotoThera, Inc.	Chief Executive Officer	January 2012 - December 2012
APT Pharmaceuticals, Inc.	President & Chief Executive Officer	2006 - 2011	Also served on the board of directors
Avigen, Inc.	Board Member	2007 - 2009	Merged with MediciNova in December 2009
Chiron BioPharma	Chief Medical Officer & Senior VP of Development	2003 - 2006
Genentech, Inc.	Vice President of Development Sciences	2002 - 2003
Genentech, Inc.	Vice President of Medical Affairs	1998 - 2001
SmithKline Beecham, PLC	Various Management Positions	1988 - 1998

Fixed Compensation

Data from FY 2024

Component Name	Amount (USD)	Payment Schedule	Additional Details
Salary	$713,550	Annual 2024	Base salary for 2024
Stock Awards	$437,446	Annual 2024	Grant date fair value of restricted stock units and restricted stock awards based on closing stock price
Option Awards	$1,732,961	Annual 2024	Grant date fair value of stock options per FASB ASC Topic 718
All Other Compensation	$53,800	Annual 2024	Includes $40,000 travel allowance and $13,800 401(k) matching contribution

Performance Compensation

Data from FY 2024

Bonus Structure

Base Salary: $731,000
Bonus Target: 75% of base salary equating to $535,163
Actual Bonus Payment: $535,163 reflecting 100% achievement of 2024 corporate performance goals

Performance Metrics

Metric	Target (%)	Maximum Achievement (%)
Financial growth and stability	35%	52%
Strategic ECO Synthesis™ platform deliverables	35%	52%
ECO Synthesis™ partnership	15%	23%
Organizational Development	15%	23%
Total	100%	150%

Additional Details

Thresholds: Performance goals are set above average; missing a target for any goal results in a zero payout on that specific target without nullifying the entire bonus.
Evaluation Period: Based on the 2024 performance period with goals established in February 2024 and bonus paid in early 2025.
Vesting Schedule: No vesting as the bonus is a cash incentive.